Amgen Shares Drop 5% Over Rival Lp(a) Drug Concerns
Amgen fell sharply on news tied to a competitor's Lp(a) drug, raising questions about its own cardiovascular pipeline bet.
Amgen Inc. shares declined roughly 5% in a selloff driven not by any setback in the company's own pipeline, but by developments surrounding a rival drug targeting lipoprotein(a), a genetically determined cardiovascular risk factor that has become one of the most closely watched frontiers in heart disease treatment.
The drop reflects how tightly interconnected the Lp(a) therapeutic space has become, with investor sentiment toward one player capable of rippling across the entire class. Amgen has its own Lp(a) candidate in development, and any signal — positive or negative — from a competitor's program is now treated as a read-through for the broader category.
Read more Why History Suggests a Bear Market Could Benefit Investors →
Lp(a) is a cholesterol-like particle found in the blood that is largely determined by genetics and cannot be meaningfully reduced through diet or existing standard-of-care therapies such as statins. Elevated Lp(a) levels are associated with increased risk of heart attack and stroke, making the target a significant commercial opportunity for whichever companies can bring effective treatments to market.
The selloff underscores the speculative premium embedded in Amgen's valuation tied to its cardiovascular pipeline ambitions. Investors are now reassessing the risk-reward profile of that bet, particularly as the competitive landscape in the Lp(a) space grows more crowded and clinical data from multiple programs continues to emerge.
Continue reading at Yahoo Finance.
